From the Journals

COVID vaccines safe for young children, study finds


 

FROM PEDIATRICS

TOPLINE:

COVID-19 vaccines from Moderna and Pfizer-BioNTech are safe for children under age 5 years, according to findings from a study funded by the Centers for Disease Control and Prevention.

METHODOLOGY:

  • Data came from the Vaccine Safety Datalink, which gathers information from eight health systems in the United States.
  • Analyzed data from 135,005 doses given to children age 4 and younger who received the Pfizer-BioNTech , and 112,006 doses given to children aged 5 and younger who received the Moderna version.
  • Assessed for 23 safety outcomes, including myocarditis, pericarditis, and seizures.

TAKEAWAY:

  • None of the adverse outcomes, including myocarditis or pericarditis, was detected among the children in the 21 days following receipt of either vaccine.
  • One case of hemorrhagic stroke and one case of pulmonary embolism occurred after vaccination but these were linked to preexisting congenital abnormalities.

IN PRACTICE:

“These results can provide reassurance to clinicians, parents, and policymakers alike.”

STUDY DETAILS:

The study was led by Kristin Goddard, MPH, a researcher at the Kaiser Permanente Vaccine Study Center in Oakland, Calif., and was funded by the Centers for Disease Control and Prevention.

LIMITATIONS:

The researchers reported low statistical power for early analysis, especially for rare outcomes. In addition, fewer than 25% of children in the database had received a vaccine at the time of analysis.

DISCLOSURES:

A coauthor reported receiving funding from Janssen Vaccines and Prevention for a study unrelated to COVID-19 vaccines. Another coauthor reported receiving grants from Pfizer in 2019 for clinical trials for coronavirus vaccines, and from Merck, GSK, and Sanofi Pasteur for unrelated research.

A version of this article first appeared on Medscape.com.

Recommended Reading

White House to end COVID vaccine mandate for federal workers
Covid ICYMI
New drugs in primary care: Lessons learned from COVID-19
Covid ICYMI
Study of hospitalizations in Canada quantifies benefit of COVID-19 vaccine to reduce death, ICU admissions
Covid ICYMI
Clinical trials: Top priority for long COVID
Covid ICYMI
Review supports continued mask-wearing in health care visits
Covid ICYMI
COVID boosters effective, but not for long
Covid ICYMI
Study finds COVID-19 boosters don’t increase miscarriage risk
Covid ICYMI
One in 10 people who had Omicron got long COVID: Study
Covid ICYMI
COVID nonvaccination linked with avoidable hospitalizations
Covid ICYMI
We may need a new defense against new COVID variants
Covid ICYMI